URGENT: The COVID-19 epidemic is severely impacting the progress of ALS research at the ALS Therapy Development Institute. If you are able to give, will you please provide an immediate gift to fund our lab?

 

TDI 208

Scientists at the ALS Therapy Development Institute are testing this small molecule in an attempt to address the oxidative stress observed in the cells of PALS.

Status

Type: Small Molecule
Stage: Active
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

This potential treatment was added to our pipeline in 2015 and is currently undergoing important experiments. These tests will help us better understand its pharmacokinetics and allow us to determine a prudent dosing strategy in efficacy testing.

Comment on this Topic

(All comments are moderated before they appear here.)